AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00610727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled prochlorperazine 5 mg
Description: InhaledStaccato Prochlorperazine 5 mg
Study NCT00610727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled prochlorperazine 10 mg
Description: InhaledStaccato Prochlorperazine 10 mg
Study NCT00610727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Inhaled Staccato Placebo (0 mg)
Study NCT00610727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine 10 mg IV over 5 sec
Description: Prochlorperazine 10 mg IV over 5 sec for patient qualification
Study NCT04492813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacokinetic of propofol and remifentanil
Description: Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients
Study NCT04492813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic of propofol and remifentanil
Description: Pharmacokinetic of propofol and remifentanil in both population: Obese and non Obese patients
Study NCT04069585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHA® Redensity with new anesthetic agent
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.
Study NCT04069585 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHA® Redensity with lidocaine
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
Study NCT04944498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Tarsorrhaphy
Description: A combination of levator recess, lateral tarsorrhaphy of 10 mm, and lateral canthopexy/lateral tarsal strip
Study NCT04944498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gold Weight Implant
Description: Installation of 1,5 gram gold weight implant above tarsal plate and underneath levator recess
Study NCT00799955 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo block
Description: 100 micrograms of spinal morphine
Study NCT00799955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided TAP block
Description: 1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
Study NCT00136279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linking Lives parent-based intervention
Description: Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
Study NCT00136279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linking Lives parent-based intervention
Description: Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
Study NCT02891642 — intervention group
Intervention type: DEVICE
Intervention: Immunomagnetic Detection
Description: Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.
Study NCT03176004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification
Description: A computer game is used to facilitate attention away from threatening words.
Study NCT03176004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: A computer game is used to facilitate attention away from threatening words.
Study NCT01267240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT01267240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT02787083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00094523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir
Description: Fosamprenavir
Study NCT02305524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView VivaSight SL
Description: Intubation using ETView VivaSight SL
Study NCT02305524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: intubation with macintosh laryngoscope with conventional tube
Study NCT00691561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ABLE
Description: Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
Study NCT00069823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor 40 mg orally twice daily
Study NCT00069823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo proton pump inhibitor
Description: Placebo proton pump inhibitor
Study NCT02801981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2230672
Description: It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.
Study NCT02801981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
Study NCT00187278 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biventricular Pacing
Description: Biventricular Pacemaker implant
Study NCT00187278 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RV Pacing
Description: Standard Pacemaker implant
Study NCT02868736 — intervention group
Intervention type: DEVICE
Intervention: Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test
Study NCT03040349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.
Study NCT03040349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider and Patient Tools
Description: Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr
Study NCT03040349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-blast and Webinars
Description: In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
Study NCT03872765 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laser surgery
Description: Use of CO2 laser to perform surgeries to treat chronic anal fissure
Study NCT02453256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
Study NCT02453256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab
Description: Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
Study NCT02453256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
Study NCT04439058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided left stellate ganglion block
Description: Stellate Ganglion Block (SGB) has several established clinical indications Under complete aseptic precautions an ultrasound guided left stellate ganglion block was performed. (paratracheal technique ) ( ) The patient was placed in the supine position with the head in the neutral position and slightly extended. An initial scanning was done with the ultrasound to identify the structures in this area.~The US probe was placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra was identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia were sought anterior to the C6 vertebral body and deep to the carotid artery. After skin infiltration with local anesthetic, the needle was inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli
Study NCT04439058 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound guided left stellate ganglion block
Description: Stellate Ganglion Block (SGB) has several established clinical indications Under complete aseptic precautions an ultrasound guided left stellate ganglion block was performed. (paratracheal technique ) ( ) The patient was placed in the supine position with the head in the neutral position and slightly extended. An initial scanning was done with the ultrasound to identify the structures in this area.~The US probe was placed at the level of the cricoid cartilage. The transverse process of the sixth cervical vertebra was identified by its prominent anterior tubercle. Also, the longus colli muscle and its overlying prevertebral fascia were sought anterior to the C6 vertebral body and deep to the carotid artery. After skin infiltration with local anesthetic, the needle was inserted from lateral to medial using the in-plane technique. The aim was to inject the local anesthetics deep to the prevertebral fascia and above the longus colli
Study NCT02380963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Colorado Diet with soy protein foods.
Description: Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.~Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.~Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)
Study NCT02380963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Colorado Diet with monetary payments
Description: Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.~Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.~Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend.
Study NCT00819481 — intervention group
Intervention type: DEVICE
Intervention: 3DKnee™ System
Description: Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
Study NCT01607853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)
Description: Once daily application, 3 weeks
Study NCT01607853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)
Description: Once daily application, 3 weeks
Study NCT01607853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® gel applied for 24 hours (+/- 2 hours)
Description: Once daily application, 3 weeks
Study NCT01607853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)
Description: Once daily application, 3 weeks
Study NCT03232216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3.
Description: Vitamin D3 50.000 UI in each packet of powder for oral solution.
Study NCT03232216 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.
Study NCT02548884 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary cannulation
Study NCT02437188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT (Acceptance and Commitment Therapy)
Description: The 1-day training session with ACT proposed for this study is designed to reduce behavioral avoidance and to enhance acceptance-based coping. The intervention includes: 1) Behavioral Change Training (2.5 hours) involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training (2.5 hours) emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts and learning how to willingly face experiences that cannot be changed.
Study NCT01048944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion SR
Description: 150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
Study NCT01048944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
Study NCT01048944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch and Placebo Pill
Description: 150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
Study NCT04974606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cherry-flavored still beverage
Description: 10 oz bottle
Study NCT04974606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry-flavored still beverage
Description: 10 oz bottle
Study NCT04974606 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cherry-flavored still beverage
Description: 10 oz bottle
Study NCT06005090 — intervention group
Intervention type: PROCEDURE
Intervention: Far Cortical Locking Technique
Description: Apart from the traditional 3 point fixation of the locking screw this technique compromises two point fixation of the screw where one into the plate and the other is into the far cortex of the diaphysis. The near cortex was widened by 3.2 mm of dirll bit to eliminate the fixation of the screw into the near cortex
Study NCT01421147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously
Study NCT01421147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus
Description: Administered subcutaneously
Study NCT01421147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously
Study NCT01421147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously
Study NCT03439891 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03439891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT03581955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banana Cavendish
Description: 240g of fruit plus 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)
Study NCT03581955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: 300g of raw tomato (coeur de boeuf) with refined sunflower oil (12g) and 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor).
Study NCT03581955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresubin ® 2kcal fiber neutral flavor
Description: 250 ml Fresubin ® 2kcal fiber neutral flavor
Study NCT03315598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
Study NCT02074332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity guidance
Description: Physical education class amelioration Additional physical activities for overweight\&obese students Family physical activities Parent involvement
Study NCT02074332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Knowledge of obesity prevention and control
Study NCT01469598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Docetaxel
Description: Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
Study NCT03529799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-PAS Goggles
Description: Portable, head-mounted display goggle system with integrated eye capture technology
Study NCT03529799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-PAS Goggles
Description: Portable, head-mounted display goggle system with integrated eye capture technology
Study NCT04217824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pilonidal sinus excision
Description: Closure of the defect in pilonidal sinus excision with one of the randomly selected flap methods.
Study NCT03041467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IN.PACT AV DCB
Description: IN.PACT™ AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
Study NCT03041467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Balloon Angioplasty
Description: Standard PTA Balloon
Study NCT00309023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663513
Description: mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
Study NCT01044992 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: H215O PET
Description: H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.